PDF(Pubmed)
Abstract：
UNASSIGNED: Finding a non-invasive and repeatable tool has been recommended to make an accurate diagnosis of Alzheimer\'s disease (AD) and Parkinson\'s disease (PD).
UNASSIGNED: 70 volunteers participated in three groups: 24 with mild dementia of AD, 24 in the first and second stages of PD, and 22 healthy controls. After valuing the scores of cognitive tests, the salivary levels of phosphorylated tau (p-tau), total alpha-synuclein (α-syn), and beta-amyloid 1-42 (Aβ) proteins have been evaluated. Finally, the cutoff points, receiver operating characteristic (ROC), sensitivity, and specificity have been calculated to find accurate and detectable biomarkers.
UNASSIGNED: Findings showed that the salivary level of Aβ was higher in both PD (p < 0.01) and AD (p < 0.001) patients than in controls. Moreover, the level of α-syn in both PD and AD patients was similarly lower than in controls (p < 0.05). However, the level of p-tau was only higher in the AD group than in the control (p < 0.01). Salivary Aβ 1-42 level at a 60.3 pg/ml cutoff point revealed an excellent performance for diagnosing AD (AUC: 0.81).
UNASSIGNED: Evaluation of p-tau, α-syn, and Aβ 1-42 levels in the saliva of AD and PD patients could help the early diagnosis. The p-tau level might be valuable for differentiation between AD and PD. Therefore, these hopeful investigations could be done to reduce the usage of invasive diagnostic methods, which alone is a success in alleviating the suffering of AD and PD patients. Moreover, introducing accurate salivary biomarkers according to the pathophysiology of AD and PD should be encouraged.
UNASSIGNED: 70 volunteers participated in three groups: 24 with mild dementia of AD, 24 in the first and second stages of PD, and 22 healthy controls. After valuing the scores of cognitive tests, the salivary levels of phosphorylated tau (p-tau), total alpha-synuclein (α-syn), and beta-amyloid 1-42 (Aβ) proteins have been evaluated. Finally, the cutoff points, receiver operating characteristic (ROC), sensitivity, and specificity have been calculated to find accurate and detectable biomarkers.
UNASSIGNED: Findings showed that the salivary level of Aβ was higher in both PD (p < 0.01) and AD (p < 0.001) patients than in controls. Moreover, the level of α-syn in both PD and AD patients was similarly lower than in controls (p < 0.05). However, the level of p-tau was only higher in the AD group than in the control (p < 0.01). Salivary Aβ 1-42 level at a 60.3 pg/ml cutoff point revealed an excellent performance for diagnosing AD (AUC: 0.81).
UNASSIGNED: Evaluation of p-tau, α-syn, and Aβ 1-42 levels in the saliva of AD and PD patients could help the early diagnosis. The p-tau level might be valuable for differentiation between AD and PD. Therefore, these hopeful investigations could be done to reduce the usage of invasive diagnostic methods, which alone is a success in alleviating the suffering of AD and PD patients. Moreover, introducing accurate salivary biomarkers according to the pathophysiology of AD and PD should be encouraged.
摘要：
UNASSIGNED：建议寻找一种非侵入性和可重复的工具来准确诊断阿尔茨海默病（AD）和帕金森病（PD）。
UNASSIGNED：70名志愿者分为三组：24名患有轻度AD痴呆，24在PD的第一阶段和第二阶段，和22个健康对照。在评估认知测试的分数后，磷酸化tau（p-tau）的唾液水平，总α-突触核蛋白(α-syn)，和β-淀粉样蛋白1-42（Aβ）*蛋白质已被评估。最后,截止点，接收机工作特性(ROC)，灵敏度,和特异性已被计算以找到准确和可检测的生物标志物。
UNASSIGNED：研究结果表明，PD（p<0.01）和AD（p<0.001）患者的唾液Aβ水平均高于对照组。此外，PD和AD患者的α-syn水平均低于对照组（p<0.05）。然而,AD组p-tau水平仅高于对照组(p<0.01)。60.3pg/ml截止点的唾液Aβ1-42水平显示出诊断AD的优异性能(AUC:0.81)。
未经评估：p-tau的评估，α-syn,AD和PD患者唾液中Aβ1-42的水平有助于早期诊断。p-tau水平对于区分AD和PD可能是有价值的。因此,这些有希望的调查可以减少侵入性诊断方法的使用，仅此一项就能成功减轻AD和PD患者的痛苦。此外，应鼓励根据AD和PD的病理生理学引入准确的唾液生物标志物。
UNASSIGNED：70名志愿者分为三组：24名患有轻度AD痴呆，24在PD的第一阶段和第二阶段，和22个健康对照。在评估认知测试的分数后，磷酸化tau（p-tau）的唾液水平，总α-突触核蛋白(α-syn)，和β-淀粉样蛋白1-42（Aβ）*蛋白质已被评估。最后,截止点，接收机工作特性(ROC)，灵敏度,和特异性已被计算以找到准确和可检测的生物标志物。
UNASSIGNED：研究结果表明，PD（p<0.01）和AD（p<0.001）患者的唾液Aβ水平均高于对照组。此外，PD和AD患者的α-syn水平均低于对照组（p<0.05）。然而,AD组p-tau水平仅高于对照组(p<0.01)。60.3pg/ml截止点的唾液Aβ1-42水平显示出诊断AD的优异性能(AUC:0.81)。
未经评估：p-tau的评估，α-syn,AD和PD患者唾液中Aβ1-42的水平有助于早期诊断。p-tau水平对于区分AD和PD可能是有价值的。因此,这些有希望的调查可以减少侵入性诊断方法的使用，仅此一项就能成功减轻AD和PD患者的痛苦。此外，应鼓励根据AD和PD的病理生理学引入准确的唾液生物标志物。
